Skip Nav Destination
Issues
1 February 2014
-
Cover Image
Cover Image
Ultraviolet (UV) B radiation (280–320 nm) induces squamous cell carcinoma (SCC) both in human and murine skin. WNT signaling is associated with the pathogenesis of these cancers as well as a decrease in estrogen receptor β (ERβ) expression. Using the SKH-1 hairless mouse model, topical administration of an ERβ-agonist, Erb-041, augments ERβ expression and effectively attenuates UVB-induced skin tumor number, size, and incidence with a concomitant decrease in proliferative (PCNA, cyclin D1) and angiogenic (CD31/VEGF) biomarkers. In SCCs, Erb-041 treatment downregulated the WNT/β-catenin signaling pathway as well as the phosphorylation of PI3K and AKT. The cover immunofluorescent micrograph (40×) depicts the co-localization (yellow) of WNT7b (red) and β-catenin (green) in the plasma membrane of UVB-induced, Erb-041–treated SCCs (nuclei in blue). Erb-041 treatment considerably reduced the nuclear localization of β-catenin in SCCs compared to control (not shown). Results from this study suggest a role of WNT signaling in regulating ERβ-dependent attenuation of tumor proliferation, migration, and invasiveness and that an ERβ-agonist, Erb-041, may be effective in the chemoprevention of non-melanoma skin cancers. See article by Chaudhary and colleagues (beginning on page 186) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Letter from the Editor
Commentary
Research Articles
Erb-041, an Estrogen Receptor-β Agonist, Inhibits Skin Photocarcinogenesis in SKH-1 Hairless Mice by Downregulating the WNT Signaling Pathway
Sandeep C. Chaudhary; Tripti Singh; Sarang S. Talwelkar; Ritesh K. Srivastava; Aadithya Arumugam; Zhiping Weng; Craig A. Elmets; Farrukh Afaq; Levy Kopelovich; Mohammad Athar
Author Choice
Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study
Lynn C. Hartmann; Derek C. Radisky; Marlene H. Frost; Richard J. Santen; Robert A. Vierkant; Lorelle L. Benetti; Yaman Tarabishy; Karthik Ghosh; Daniel W. Visscher; Amy C. Degnim
Impact of Vitamin D Supplementation on Inflammatory Markers in African Americans: Results of a Four-Arm, Randomized, Placebo-Controlled Trial
Paulette D. Chandler; Jamil B. Scott; Bettina F. Drake; Kimmie Ng; JoAnn E. Manson; Nader Rifai; Andrew T. Chan; Gary G. Bennett; Bruce W. Hollis; Edward L. Giovannucci; Karen M. Emmons; Charles S. Fuchs
Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model
Holly L. Nicastro; Clinton J. Grubbs; M. Margaret Juliana; Ann M. Bode; Mi-Sung Kim; Yan Lu; Ming You; Ginger L. Milne; Daniel Boring; Vernon E. Steele; Ronald A. Lubet
Application of SNP Microarrays to the Genome-Wide Analysis of Chromosomal Instability in Premalignant Airway Lesions
Ichiro Nakachi; Jessica L. Rice; Christopher D. Coldren; Michael G. Edwards; Robert S. Stearman; Steven C. Glidewell; Marileila Varella-Garcia; Wilbur A. Franklin; Robert L. Keith; Marina T. Lewis; Bifeng Gao; Daniel T. Merrick; York E. Miller; Mark W. Geraci
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.